sur Zomedica Corp. (NASDAQ:ZOM)
Zomedica Enhances TRUFORMA Platform with Feline Assay Extension
Zomedica Corp. has announced the expansion of its TRUFORMA diagnostic platform by including feline testing for its cobalamin and folate assay. Initially launched in 2024 for dogs, this multiplexed assay is unique in offering both cobalamin and folate testing in-clinic. Veterinarians had previously expressed a need to extend this testing to cats.
Deborah Greco, DVM, emphasized the importance of timely results for feline patients with gastrointestinal disease, noting rapid deterioration compared to canines. With the ability to receive results in under 25 minutes, the platform allows for immediate adjustment of treatment.
Michael Mockler, Zomedica's Senior Product Manager, highlighted the efficiency and practice profitability that the TRUFORMA platform offers. This expansion signifies a crucial advancement in veterinary diagnostic capabilities.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Zomedica Corp.